Integrating ePReBMs From Phoenix in Respiratory Diseases

Sponsor
University of Alberta (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05827302
Collaborator
(none)
40
1
60

Study Details

Study Description

Brief Summary

Participants with respiratory disease experience often a worsening of their condition, with increasing symptoms such as cough and shortness of breath. This worsening, often called exacerbation or flare up, impacts on the life of the participants, since they become limited in their daily activities.

Healthcare is still based today on limited times for clinical appointments to perform investigations and to meet with specialists/clinicians. Very often, these evaluations do not reflect the way the disease is limiting the patient's life.

Wearable devices offer the opportunity to collect data on physical activities and important clinical parameters (such as how the patient is active or just staying in bed during the day), on a daily basis.

The HG Phoenix AI- based Smart Watch produced by Health Gauge, an Albertan company based in Edmonton, has the potential to measure heart rate, heart rate variability, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep pattern (deep, light sleep, awake time), duration and time, daily physical activities (site count and distance) and calories burnt in a simple and non-invasive fashion. Ideally, these parameters could be monitored and recorded 24 hours per 7 days per week.

This study aims to demonstrate that this device can be used for a long time at home and it is comfortable to use for the participants, that it is not dangerous and, possibly, that it can help to identify exacerbations before the currently available investigations.

Condition or Disease Intervention/Treatment Phase
  • Device: Health Gauge AI-Based Wearable Device - Model: Phoenix
N/A

Detailed Description

Participants will be asked to wear the Health Gauge AI-based Wearable Device for at least 8 hours per day (ideally 24 hours), 3 days per week, for 6 months. The following data will be continuously collected from the wearable device:

heart rate, blood pressure, pulse wave velocity, respiratory rate, temperature, arterial saturation, sleep patterns, daily physical activities (step count and distance), and calories burnt.

Clinical data including demographics, radiographic, cardiac and lung functioning, diagnosis, and comorbidities will be collected from the participant's electronic medical record at baseline, 3 months, and 6 months.

Quality of life questionnaires (Saint George Respiratory Questionnaire, Medical Research Council Dyspnea Score, and EQ5-DL) will be completed by the participant through the Zamplo digital app at baseline, 3 and 6-month time points. A questionnaire on participant experience will also be administered at the 3 and 6-month time points.

Participants will be called monthly to assess patient-reported compliance with the wearable device, and adverse events (including emergency room visits and hospitalizations).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
The study will compare healthy controls to those with respiratory disease. Both groups will be wearing the watch and completing the same questionnairesThe study will compare healthy controls to those with respiratory disease. Both groups will be wearing the watch and completing the same questionnaires
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Integrating Electronic Patient Reported Biometric Measures (ePReBMs) From the Health Gauge Phoenix Smart Watch in Respiratory Diseases
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Apr 1, 2028
Anticipated Study Completion Date :
Apr 1, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Device: Health Gauge AI-Based Wearable Device - Model: Phoenix

Device: Health Gauge AI-Based Wearable Device - Model: Phoenix
Wearable device

Outcome Measures

Primary Outcome Measures

  1. Length of time wearing device [6 months]

    Total length of time participant wears device

Secondary Outcome Measures

  1. Prediction of respiratory exacerbations- Number of emergency room visits or hospitalizations [6 months]

    Explore the possibility to predict exacerbations/flares up of the respiratory condition of the patients

  2. Adverse Events [6 months]

    Number of adverse events

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Male or female volunteers, at least 18 years of age at the time of screening visit;

  2. Fluent in English and able to follow the instructions to use the Health Gauge AI-based Wearable Device;

  3. Willing and cognitively able to sign informed consent

  4. Interstitial lung disease, chronic obstructive pulmonary disease, pulmonary hypertension, or a healthy control

Exclusion Criteria:
  1. Pregnancy;

  2. History of active (clinically significant) skin disorders;

  3. History of allergic response to plastic materials;

  4. Subjects with electronic implants of any kind (e.g. pacemaker);

  5. Broken, damaged or irritated skin or rashes near the sensor application sites;

  6. Subjects who are physically or cognitively unable to normally perform activities of daily living, assessed at the discretion of the investigator.

Exclusion Criteria for healthy control only:
  1. An active medical conditions for which they are on chronic treatment with drugs;

  2. Shortness of breath (any sort);

  3. Chronic cough;

  4. Fatigue or difficulty sleeping.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Alberta

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Alberta
ClinicalTrials.gov Identifier:
NCT05827302
Other Study ID Numbers:
  • Pro00125759
First Posted:
Apr 25, 2023
Last Update Posted:
Apr 26, 2023
Last Verified:
Mar 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2023